[Recent advances in the adjuvant treatment of high-risk melanoma]

Area of Science:

• Oncology
• Dermatology
• Clinical Trials

Background:

• Metastatic melanoma prognosis remains challenging despite recent therapeutic advancements.
• Adjuvant therapy after high-risk melanoma resection is a critical area of ongoing research.
• Targeted therapies and immunotherapies initially for metastatic disease show promise in the adjuvant setting.

Purpose of the Study:

• To summarize current clinical research in adjuvant therapy for high-risk melanoma.
• To discuss the implications of recent phase 3 trial results for clinical practice.
• To provide an overview of practice-changing innovations in melanoma management.

Main Methods:

• Review of phase 3 clinical trials investigating adjuvant therapies for high-risk melanoma.
• Analysis of data on small-molecule targeted therapy efficacy.
• Evaluation of immune checkpoint inhibitor therapy effectiveness in the adjuvant setting.

Main Results:

• Both targeted small-molecule therapies and immune checkpoint inhibitors have demonstrated significant efficacy in phase 3 adjuvant trials.
• These findings represent a shift in the standard of care for high-risk melanoma patients.
• The results are considered practice-changing, impacting current treatment strategies.

Conclusions:

• Adjuvant targeted therapy and immune checkpoint inhibitors are effective in improving outcomes for resected high-risk melanoma.
• These therapies offer new hope and improved prognosis for patients.
• Clinical management of high-risk melanoma is evolving due to these therapeutic breakthroughs.